ETON - Company ID 0001710340
Eton Pharmaceuticals, Inc. trades as ETON. In its fiscal 2025 annual report the company posted revenue of $79.95M, up 104.9% from the prior year and net income of -$4.60M. This page tracks Eton Pharmaceuticals, Inc. through 371 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 6 fiscal years Eton Pharmaceuticals, Inc.'s revenue grew from $959.00K to $79.95M, a compound annual growth rate of 109.0%. Net profit margin expanded from -1910.3% to -5.8% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-27 |
| Insider sale notice | 144 | 2026-05-22 |
| Major company event | 8-K | 2026-05-19 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Major company event | 8-K | 2026-05-01 |
| Major company event | 8-K | 2026-04-27 |
| Proxy statement | DEF 14A | 2026-04-24 |
The largest companies sharing Eton Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Eton Pharmaceuticals, Inc. reported revenue of $79.95M for fiscal year 2025, an increase of 104.9% year over year.
In its latest fiscal year Eton Pharmaceuticals, Inc. reported a net loss of $4.60M.